Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

Whether Alzheimer's Disease is Responsive to a Single Oral Dose of Donepezil and this Response is Predictive Factor in Alzheimer's Disease

일회 Donepezil 투약이 알쯔하이머병 환자에 미치는 영향 및 반응군 예측 인자로서의 가능성

  • Received : 2010.11.11
  • Accepted : 2011.01.10
  • Published : 2011.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : Though a proportion of Alzheimer's disease(AD) patients treated with donepezil have shown positive response on cognition, but the responders' characteristics are still uncertain. This study attempts to identify whether a single oral dose of donepezil(5mg) can change cognition and the relationship between single dose responder items and long-term responder are examined. Methods : Twenty-three AD patients for single donepezil challenge study group and eleven AD patients for controls were participated in the study. Seven days after baseline study for neuropsychological test and EEG, same studies were rechecked after donepezil medication in study group. In donepezil study groups, 12 weeks after donepezil medication, neuropsychological test and EEG were rechecked. Results : After single donepezil challenge, forward digit span, Rey-Osterrieth Complex Figure Test copy, SVLT delayed recall were significantly improved, and beta spectra power in anterior, theta spectra power in posterior field were significantly decreased. According to linear regression analysis, forward digit span after single donepezil challenge was significantly positive correlated with long-term responders. Conclusions : This study suggests that single donepezil medication can significantly change cognitive functions and EEG in AD patients. Among these responsive items, forward digit span was significantly correlated with long-term responder.

Keywords

References

  1. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-1239. https://doi.org/10.1126/science.7058341
  2. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126. https://doi.org/10.1002/ana.410100203
  3. Giacobini E. Pharmacotherapy of Alzheimer disease: new drugs and novel strategies. Prog Brain Res 1993;98:447-454.
  4. Davis RE, Doyle PD, Carroll RT, Emmerling MR, Jaen J. Cholinergic therapies for Alzheimer's disease. Palliative or disease altering? Arzneimittelforschung 1995;45:425-431.
  5. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158:1021-1031. https://doi.org/10.1001/archinte.158.9.1021
  6. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145. https://doi.org/10.1212/WNL.50.1.136
  7. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131-145. https://doi.org/10.1097/00019442-200303000-00004
  8. Schneider LS, Qizilbash N. Delay in nursing home placement with donepezil. J Am Geriatr Soc 2004;52:1024-1026.
  9. Kwak YT, Han IW, Bang OY. Changes of quantitative EEG after donepezil treatment in alzheimer's disease. J Korean Neurol Assoc 2001;19:245-250.
  10. Giacobini E. Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 2000;14 Suppl 1:S3-S10.
  11. Wilcock GK. The treatment of Alzheimer's disease with anticholinesterase drugs. Alzheimer Rev 1993;4:73-77.
  12. Byrne EJ, Arie T. Tetrahydroaminoacridine and Alzheimer's disease. BMJ 1994;308:868-869. https://doi.org/10.1136/bmj.308.6933.868
  13. Winker MA. Tacrine for Alzheimer's disease. Which patient, what dose? JAMA 1994;271:1023-1024. https://doi.org/10.1001/jama.1994.03510370075036
  14. Schneider LS, Lyness SA, Pawluczyk S, Gleason RP, Sloane RB. Do blood pressure and age predict response to tacrine(THA) in Alzheimer's disease? A preliminary report. Psychopharmacol Bull 1991;27:309-314.
  15. Kanetaka H, Hanyu H, Hirao K, Shimizu S, Sato T, Akai T, et al. Prediction of response to donepezil in Alzheimer's disease: combined MRI analysis of the substantia innominata and SPECT measurement of cerebral perfusion. Nucl Med Commun 2008;29:568-573. https://doi.org/10.1097/MNM.0b013e3282f5e5f4
  16. Hanyu H, Shimizu T, Tanaka Y, Takasaki M, Koizumi K, Abe K. Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2003;15:177-182. https://doi.org/10.1159/000068785
  17. Riekkinen P Jr, Riekkinen M, Soininen H, Kuikka J, Laakso M, Riekkinen P Sr. Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease. Neuroreport 1997;8:1845-1849. https://doi.org/10.1097/00001756-199705260-00011
  18. Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, et al. Further analysis of the cognitive effects of tetrahydroaminoacridine(THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology (Berl) 1993;110:395-401. https://doi.org/10.1007/BF02244644
  19. Alhainen K, Partanen J, Reinikainen K, Laulumaa V, Soininen H, Airaksinen M, et al. Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease. Neurosci Lett 1991;127:113-116. https://doi.org/10.1016/0304-3940(91)90907-B
  20. Pietrzak RH, Maruff P, Snyder PJ. Methodological improvements in quantifying cognitive change in clinical trials: an example with single-dose administration of donepezil. J Nutr Health Aging 2009;13:268-273. https://doi.org/10.1007/s12603-009-0071-4
  21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34: 939-944. https://doi.org/10.1212/WNL.34.7.939
  22. Kang Y, Na DL, Hahn S. A validity study on the Korean Mini-Mental State Examination(K-MMSE) in dementia patients. J Korean Neurol Assoc 1997;15:300-308.
  23. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572. https://doi.org/10.1192/bjp.140.6.566
  24. Kang Y. Samsung Neuropsychological Screening Battery. In: Current research in dementia. Seoul: The Korean Dementia Association 1998;99-107.
  25. Bendat JS, Piersol AP. Random Data Analysis and Measurement Procedures. 2nd ed. New York: Wiley Interscience Press;1986. p.121-132.
  26. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41:719-739. https://doi.org/10.2165/00003088-200241100-00003
  27. Kwak YT, Han IW, Kim J, Lee YS. The change of KMMSE following donepezil medication in patients with Alzheimer's disease and small vessel dementia, and the characteristics of Alzheimer's disease with meaningful K-MMSE change. Korean J Biol Psychiatry 2005;12:98-106.
  28. Doraiswamy PM, Kaiser L, Bieber F, Garman RL. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord 2001;15:174-183. https://doi.org/10.1097/00002093-200110000-00003
  29. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 1992;268:2523-2529. https://doi.org/10.1001/jama.1992.03490180055026
  30. Jahanshahi M, Saleem T, Ho AK, Fuller R, Dirnberger G. A preliminary investigation of the running digit span as a test of working memory. Behav Neurol 2008;20:17-25. https://doi.org/10.1155/2008/195684
  31. Callaway E, Halliday R, Naylor H. Cholinergic activity and constraints on information processing. Biol Psychol 1992;33:1-22. https://doi.org/10.1016/0301-0511(92)90002-C
  32. Sunderland T, Tariot PN, Newhouse PA. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res 1988;472:371-389. https://doi.org/10.1016/0006-8993(88)91227-9
  33. Snyder PJ, Bednar MM, Cromer JR, Maruff P. Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimers Dement 2005;1:126-135. https://doi.org/10.1016/j.jalz.2005.09.004
  34. Almkvist O, Jelic V, Amberla K, Hellstrom-Lindahl E, Meurling L, Nordberg A. Responder characteristics to a single oral dose of cholinesterase inhibitor: a doubleblind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord 2001;12:22-32. https://doi.org/10.1159/000051232
  35. McLendon BM, Doraiswamy PM. Defining meaningful change in Alzheimer's disease trials: the donepezil experience. J Geriatr Psychiatry Neurol 1999;12:39-48. https://doi.org/10.1177/089198879901200108
  36. Eagger SA, Levy R. Serum levels of tacrine in relation to clinical response in Alzheimer's disease. Int J Geriatr Psychiatry 1992;7:115-119. https://doi.org/10.1002/gps.930070208
  37. Pomara N, Deptula D, Singh R. Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine(HP 029) in Alzheimer's disease. Psychopharmacol Bull 1991;27:301-307.